Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer:

Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer: Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and safety of this novel treatment and other treatments that are being evaluated in this disease. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Medicine Insights: Oncology SAGE

Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer:

Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer:

Clinical Medicine Insights: Oncology , Volume 6: 1 – Oct 31, 2012

Abstract

Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and safety of this novel treatment and other treatments that are being evaluated in this disease.

Loading next page...
 
/lp/sage/efficacy-and-tolerability-of-pharmacotherapy-options-for-the-treatment-RnUPoBVXM1
Publisher
SAGE
Copyright
Copyright © 2022 by SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
eISSN
1179-5549
DOI
10.4137/cmo.s8305
Publisher site
See Article on Publisher Site

Abstract

Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and safety of this novel treatment and other treatments that are being evaluated in this disease.

Journal

Clinical Medicine Insights: OncologySAGE

Published: Oct 31, 2012

Keywords: medullary thyroid cancer; pharmacotherapy; tyrosine kinase inhibitors; vandetanib

References